FinancialContent is the trusted provider of stock market information to the media industry.
More NewsRead More
Galectin Therapeutics Announces Complete Enrollment in its Phase 2 Trial with GR-MD-02 in NASH Patients with Advanced Fibrosis
May 11, 2016
Galectin Therapeutics Reports First Quarter 2016 Financial Results and Provides Business Update
May 10, 2016
Preclinical Research on the Role of Galectin-3 in Pulmonary Arterial Hypertension to be Presented at the American Thoracic Society 2016 International Conference
May 05, 2016
Galectin Therapeutics to Present at Needham & Company’s 15th Annual Healthcare Conference
April 07, 2016
Galectin Therapeutics Receives U.S. Patent Allowance for GR-MD-02 to Treat Pulmonary Fibrosis
February 24, 2016
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here